| Metric | Value ($ M) | Q2 FY25 | Q3 FY24 |
|---|---|---|---|
| Revenue | 3.08 | 6.9% | 20.4% |
| Total Income | 3.08 | 6.9% | 20.4% |
| Expenditure | 11.39 | 3.4% | 4.1% |
| PBT | -17.45 | 135.2% | 131.7% |
| Net Profit | -17.45 | 135.2% | 131.7% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.25 | 108.3% | 13.8% |
Opus Genetics Announces Q3 2025 Financial Results and Corporate Update
04 May 2026 · 4 May, 7:22 am
Summary
Opus Genetics announced its financial results for the third quarter ended September 30, 2025. The company reported license and collaborations revenue of $3.1 million for the quarter. As of September 30, 2025, cash and cash equivalents totaled $30.8 million, which was subsequently bolstered by approximately $23.0 million in gross proceeds from a registered direct offering. The company anticipates that its existing cash resources will fund operations into the second half of 2027.
Key Highlights
- 1
Opus Genetics reported positive 3-month pediatric and 18-month adult clinical data from the OPGx-LCA5 Phase 1/2 trial, indicating potential for restoring cone-mediated vision.
- 2
The company had a successful FDA RMAT meeting, which provides the potential for an accelerated regulatory pathway to approval for OPGx-LCA5.
- 3
The OPGx-BEST1 gene therapy program is underway, with recruitment ongoing in the Phase 1/2 trial for the treatment of BEST1 disease.
- 4
A Supplemental New Drug Application submission is planned by year-end 2025 for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia.
- 5
The company strengthened its capital position through a recent equity offering and non-dilutive funding from patient advocacy groups.
- 6
License and collaborations revenue totaled $3.1 million for the third quarter of 2025.
- 7
As of September 30, 2025, Opus Genetics had cash and cash equivalents of $30.8 million.
Management Comments
George Magrath
M.D.
“We have taken critical steps in advancing our pipeline, including the positive data and successful outcome of our recent FDA meeting regarding our LCA5 program and the opening of recruitment in our BEST1 Phase 1/2 clinical trial,” “We look forward to continuing this momentum into next year, when we expect multiple data readouts across several programs. The financing we recently completed reinforces the strong support from existing shareholders and new prominent healthcare investors and provides us with financial resources to expedite the path toward multiple approvals.”
Informational and educational content only. Not investment advice.